Reading a peptide study: the evidence ladder

Why 'backed by research' means so little

Almost every peptide sold online is described as researched, and in a narrow sense that is true: there are papers. What the phrase hides is what kind of papers. A study of cells in a dish, a study of rats, a report on two patients and a randomised trial in two thousand people are all 'research'. They answer completely different questions, and only the last kind answers the question a buyer is really asking: will this do what is claimed, in people like me, and at what risk?

Scientists arrange evidence as a ladder, or a pyramid, with the weakest kinds at the bottom and the strongest at the top. The rungs below follow that order, each with a real paper about a peptide, chosen from studies already cited on our encyclopedia entries. The point is not that the lower rungs are worthless. Most drugs begin there. The point is that a claim can only be as strong as the highest rung it reaches.

Rung 1: cells in a dish

In vitro studies, Latin for 'in glass', put a peptide on cells grown in a dish and measure what changes. They are fast, cheap and good at showing mechanism: which receptor a molecule binds, which genes it switches on. A 2014 study found that BPC-157 increased growth hormone receptor expression in cultured tendon fibroblasts in a time- and dose-dependent way ¹, and an earlier one found that it sped the outgrowth and migration of tendon cells from rat Achilles tendon explants ².

What a cell study cannot tell you is whether any of it happens in a living body. A dish has no digestion, no blood flow, no liver breaking the molecule down and no immune system reacting to it. Concentrations are set by the researcher, often far higher than anything an injection could achieve at the tissue. When a seller says a peptide 'activates 4,000 genes' or 'upregulates growth factors', the claim usually comes from this rung.

Rung 2: animals

Animal studies give the peptide to a whole organism, usually a mouse or a rat, often after deliberately injuring it. They add the things a dish lacks: absorption, distribution, metabolism and a body's response. In one, rats with crushed calf muscles healed better on functional, biomechanical and microscopic measures when given BPC-157 ³. Studies like this are a real step up, and they are the backbone of the BPC-157 literature: 105 of its 224 PubMed records are indexed as animal-only research ⁴.

The limits are well known. Rodents differ from people in metabolism, body size and how they heal; injuries made in a laboratory are uniform in a way human injuries are not; and many animal studies are small, unblinded and run by the group that discovered the compound. Most treatments that work in animals do not go on to work in human trials. An animal result is a reason to test in people, not evidence that people will benefit.

Rung 3: case reports and series

The first human evidence is often a description of what happened to a handful of patients, with no comparison group. In a 2025 pilot, two adults at a private clinic received intravenous BPC-157 at 10 mg and then 20 mg, and the authors reported no changes in cardiac, liver, kidney, thyroid or glucose markers ⁵. That is useful as a first look at safety, and it is honest about its size.

What it cannot show is effectiveness, or rare harms. With two people, a side effect that strikes one person in a hundred would almost certainly be missed. Without a comparison group, any improvement could be due to time, rest, other treatment or expectation. Testimonials, clinic case series and before-and-after photos all sit on this rung or below it.

Rung 4: small controlled trials

A controlled trial compares people who get the treatment with people who do not, ideally assigned by chance, which is what 'randomised' means, and ideally without either side knowing who got what, which is 'blinding'. Even a small randomised trial is a big step up, because chance assignment balances the things researchers cannot measure.

GHK-Cu, the copper peptide in many skin products, has a small randomised trial that illustrates both the strength and the limit. Thirteen patients completed a randomised trial of skin care after laser resurfacing with or without GHK-Cu. Computer analysis and blinded evaluators found no difference in redness, wrinkles or overall skin quality at 12 weeks, although patients using GHK-Cu rated their own skin higher on a questionnaire ⁶. That is a real test, and the split between the blinded measures and the patients' own ratings is exactly the kind of detail an abstract can hide. But with thirteen people, a modest benefit could also have been missed. A small trial can be suggestive or reassuring; it rarely settles a question. Early safety trials sit here too: thymosin beta-4, the parent protein of TB-500, was given intravenously to healthy volunteers in a randomised, placebo-controlled phase 1 study designed to test safety and tolerance, not benefit ⁷.

Rung 5: large randomised trials

At the top of primary research are large randomised controlled trials, usually phase 3, designed to answer a specific question with enough people to be sure. STEP 1 randomised 1,961 adults without diabetes to weekly semaglutide or placebo; after 68 weeks, average weight loss was 14.9% against 2.4% ⁸. SELECT went further, randomising 17,604 adults with heart disease and overweight to test whether semaglutide reduced heart attacks, strokes and cardiovascular deaths; it cut those events by 20% over about three years ⁹.

Trials like these are expensive and slow, which is why they exist mainly for drugs a company intends to have approved. That is also why the gap between approved and research peptides is so wide in the evidence: semaglutide has 309 PubMed records indexed as randomised trials; BPC-157 has 0, TB-500's search finds 7, all of them trials of the full thymosin beta-4 protein rather than the fragment sold online, and GHK-Cu has 3 ⁴.

Rung 6: systematic reviews and meta-analyses

Above single trials sit systematic reviews, which search for every study on a question using a stated method, and meta-analyses, which pool the trials' numbers. A good one is the strongest evidence there is, because it shows whether findings hold up across many studies. A 2021 meta-analysis of 19 randomised, double-blind, controlled trials in 1,125 people found that hydrolysed collagen improved skin hydration and elasticity compared with placebo ¹⁰.

But a review is only as good as what it pools, and the word 'systematic' does not lift weak studies. A 2025 systematic review of BPC-157 in orthopaedic sports medicine searched three databases; the support it found for healing in fracture, tendon, ligament and muscle injury was preclinical, and it noted that clinicians and athletes use the compound anyway ¹¹. A 2025 review of anti-wrinkle peptides found a surprising absence of clinical studies of GHK-Cu itself ¹². Read the conclusion of a review for what it says about the evidence, not just for its title.

Four questions that sort any paper

Who or what was studied? Cells, animals or people, and if people, which people. A result in young athletes may not apply to older adults; a result in mice does not apply to anyone yet. The abstract usually says in its first lines.

Was there a comparison group, and was it randomised and blinded? Without a comparison, improvement cannot be credited to the treatment. Without randomisation, the groups may differ in ways that explain the result. Without blinding, expectation can.

How many, and for how long? Small numbers miss real effects and rare harms; short follow-up misses what happens later. Two patients for a few days is a different thing from two thousand for a year.

What exactly was measured? A blood marker, a scan or a questionnaire is not the same as a person feeling better, healing faster or living longer. Trials often report many outcomes; look for the one named in advance as primary, and whether it was met.

Two extra checks are worth the time. Who paid for the study, and who ran it? Industry funding and discoverer-led research are common and not disqualifying, but they are reasons to look for independent replication. And is the paper still standing? Our encyclopedia checks every cited paper for retractions, because some peptide claims rest on papers that were later withdrawn.

Red flags in how research is cited

Sellers and forums cite studies to sound authoritative, and the citation itself often gives the game away. Watch for a claim about people backed only by a paper about rats or cells; for a 'study' that turns out to be a review by the compound's own discoverers, summarising their earlier work; for a link to a conference abstract that was never published in full; and for numbers that appear nowhere in the paper cited. Our dihexa entry shows another trap: the paper most often cited for its mechanism has been retracted, yet the claim keeps circulating. And FOXO4-DRI shows how a single mouse paper can sustain a market for a decade.

The fix is simple, if tedious: open the paper, or at least its PubMed abstract, and check that it says what it is said to say, about the species it is said to be about. Every study card on our encyclopedia links to its PubMed record for exactly that reason.

How this maps to our grades

Our evidence grades compress the ladder into three levels, and they grade the quality of the human evidence, not whether a compound works ¹³. A high grade means efficacy has been tested in controlled human trials large enough to answer the question, typically a completed phase 3 programme or an approval dossier; 148 of our 348 entries are graded high. Medium means people have taken it under study conditions with published results, but short of a completed phase 3; 99 entries. Low means there is no human efficacy evidence worth relying on, only cell, animal or case-report evidence; 101 entries, including BPC-157, TB-500 and GHK-Cu ¹³.

A high grade is not a recommendation, and several high-graded compounds failed their main trials: the grade describes how well the question was tested, not the answer. Our Evidence Explorer shows the shape of the literature behind every entry, counted rung by rung, and our methodology page sets out how grades are assigned.

Frequently asked questions

Is BPC-157 proven?

No. Its research is mostly in cells and animals; of 224 PubMed records, 0 are indexed as randomised controlled trials, and the published human data are case-level. We grade its human evidence low.

What is the strongest kind of evidence?

Large randomised controlled trials, and systematic reviews or meta-analyses that pool several good trials. Cell and animal studies come first in development but cannot show that a treatment helps people.

Does an animal study mean a peptide works in humans?

No. Most treatments that work in animals do not go on to work in human trials. An animal result is a reason to test in people, not evidence that people will benefit.

What does randomised and blinded mean?

Randomised means chance decides who gets the treatment, which balances the groups; blinded means participants, and ideally researchers, do not know who got what, which stops expectation colouring the results.

Related on Grey Peptides

• How we grade evidence
• Evidence Explorer
• BPC-157

Sources

1. Chang, C. H., et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 19(11), 19066-77. PMID: 25415472
2. Chang, C. H., et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985), 110(3), 774-80. PMID: 21030672
3. Novinscak, T., et al. (2008). Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today, 38(8), 716-25. PMID: 18668315
4. Grey Peptides evidence counts (_ops/evidence_counts.json): PubMed records by study type and species for each entry, with queries, read October 3, 2026.
5. Lee, E., et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 31(5), 20-24. PMID: 40131143
6. Miller, T. R., et al. (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 8(4), 252-9. PMID: 16847171
7. Ruff, D., et al. (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci, 1194, 223-9. PMID: 20536472
8. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 384(11), 989-1002. PMID: 33567185
9. Lincoff, A. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med, 389(24), 2221-2232. PMID: 37952131
10. de Miranda, R. B., et al. (2021). Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis. Int J Dermatol, 60(12), 1449-1461. PMID: 33742704
11. Vasireddi, N., et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 21(4), 485-495. PMID: 40756949
12. Mortazavi, S. M., et al. (2025). Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts, 15, 30071. PMID: 39963574
13. Grey Peptides methodology: how evidence is graded, with grade counts from the encyclopedia dataset. Read October 3, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.